ArticleComprehensive Physiology2021
Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.
Article in Comprehensive Physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Transition From Pulmonary to Gastrointestinal Hemorrhage: A Rare Case of Hematemesis in an Adolescent With Chronic Pulmonary Hypertension and Valvular Regurgitation.Clinical case reports · 2026Article
- Diagnostic performance of the main pulmonary artery-to-ascending aorta diameter ratio for pulmonary hypertension defined by mean pulmonary arterial pressure in children with left-to-right shunt congenital heart disease.Quantitative imaging in medicine and surgery · 2026Article
- Growth-adjusted reference values for the main pulmonary artery-to-ascending aorta ratio derived from clinically indicated chest CT in children.European radiology · 2026Article
- Pulmonary arterial hypertension caused by compression of the left lower pulmonary vein in children.Journal of cardiothoracic surgery · 2026Article
- Cardiac Magnetic Resonance Findings and Their Association with Clinical Outcomes in Pediatric Pulmonary Arterial Hypertension: An Exploratory Study.Journal of clinical medicine · 2026Article
- Review
- Unveiling the Link Between COVID-19 and Pulmonary Hypertension.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Can Milrinone Be a Therapeutic Alternative in Persistent Pulmonary Hypertension of the Newborn? A Case Series and Narrative Review.Pediatric reports · 2025Article
- Atrial Septal Defects: From Embryology to Pediatric Pulmonary Hypertension.Journal of clinical medicine · 2025Review
- Sound Waves Versus Pressure Waves: The Increasing Role of Echocardiography and Noninvasive Vasoreactivity Testing in Pediatric Pulmonary Hypertension Management.Echocardiography (Mount Kisco, N.Y.) · 2025Article
- [NDUFAF2 gene mutation presenting as primary pulmonary hypertension: a case report].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- The Role of Early Child Nutrition in Pulmonary Hypertension-A Narrative Review.Children (Basel, Switzerland) · 2024Review
- Extracorporeal membrane oxygenation (ECMO) support for children with pulmonary hypertension: A single-institutional experience of outcomes.Pulmonary circulation · 2024Article
- Acute respiratory failure due to pulmonary exacerbation in children with cystic fibrosis admitted in a pediatric intensive care unit: outcomes and factors associated with mortality.Respiratory research · 2024Article
- Notch Signaling Is Associated with Pulmonary Fibrosis in Patients with Pigeon Breeder's Lung by Regulating Oxidative Stress.Emergency medicine international · 2024Article
- Association and risk factors of pediatric pulmonary hypertension with obstructive sleep apnea: A national study utilizing the Kids' Inpatient Database (KID).International journal of pediatric otorhinolaryngology · 2023Article
- Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization.Pharmaceutics · 2022Article
- Explainable machine learning models for predicting 30-day readmission in pediatric pulmonary hypertension: A multicenter, retrospective study.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pediatric pulmonary hypertension (PPH) is a multifactorial disease with diverse etiologies and presenting features. Pulmonary hypertension (PH), defined as elevated pulmonary artery pressure, is the presenting feature for several pulmonary vascular diseases. It is often a hidden component of other lung diseases, such as cystic fibrosis and bronchopulmonary dysplasia. Alterations in lung development and genetic conditions are an important contributor to pediatric pulmonary hypertensive disease, which is a distinct entity from adult PH. Many of the causes of pediatric PH have prenatal onset with altered lung development due to maternal and fetal conditions. Since lung growth is altered in several conditions that lead to PPH, therapy for PPH includes both pulmonary vasodilators and strategies to restore lung growth. These strategies include optimal alveolar recruitment, maintaining physiologic blood gas tension, nutritional support, and addressing contributing factors, such as airway disease and gastroesophageal reflux. The outcome for infants and children with PH is highly variable and largely dependent on the underlying cause. The best outcomes are for neonates with persistent pulmonary hypertension (PPHN) and reversible lung diseases, while some genetic conditions such as alveolar capillary dysplasia are lethal. © 2021 American Physiological Society. Compr Physiol 11:2135-2190, 2021.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.